Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
Open Access
- 19 August 2011
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 34 (9), 2072-2077
- https://doi.org/10.2337/dc10-2421
Abstract
OBJECTIVE To investigate whether the dipeptidyl peptidase-4 inhibitor vildagliptin improves endothelium-dependent vasodilatation in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS Sixteen subjects with type 2 diabetes (age 59.8 ± 6.8 years, BMI 29.1 ± 4.8 kg/m2, HbA1c 6.97 ± 0.61) on oral blood glucose–lowering treatment were included. Participants received vildagliptin 50 mg b.i.d. or acarbose 100 mg t.i.d. for four consecutive weeks in a randomized, double-blind, cross-over design. At the end of each treatment period, we measured forearm vasodilator responses to intra-arterially administered acetylcholine (endothelium-dependent vasodilator) and sodium nitroprusside (endothelium-independent vasodilator). RESULTS Infusion of acetylcholine induced a dose-dependent increase in forearm blood flow in the experimental arm, which was higher during vildagliptin (3.1 ± 0.7, 7.9 ± 1.1, and 12.6 ± 1.4 mL ⋅ dL−1 ⋅ min−1 in response to three increasing dosages of acetylcholine) than during acarbose (2.0 ± 0.7, 5.0 ± 1.2, and 11.7 ± 1.6 mL ⋅ dL−1 ⋅ min−1, respectively; P = 0.01 by two-way ANOVA). Treatment with vildagliptin did not significantly change the vascular responses to sodium nitroprusside. CONCLUSIONS Four weeks’ treatment with vildagliptin improves endothelium-dependent vasodilatation in subjects with type 2 diabetes. This observation might have favorable cardiovascular implications.This publication has 27 references indexed in Scilit:
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesThe Lancet, 2010
- Assessing the cardio–cerebrovascular safety of vildagliptin: meta‐analysis of adjudicated events from a large Phase III type 2 diabetes populationDiabetes, Obesity and Metabolism, 2010
- The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 DiabetesDiabetes Care, 2010
- Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled studyInternational Journal of Clinical Practice, 2009
- Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesityCell and tissue research, 2008
- Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepirideAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive ratsJournal of Hypertension, 2003
- Diabetes and Endothelial Dysfunction: A Clinical PerspectiveEndocrine Reviews, 2001
- The Glucagon-Like PeptidesEndocrine Reviews, 1999
- Measuring Forearm Blood Flow and Interpreting the Responses to Drugs and MediatorsHypertension, 1995